Xlear Inc. centers on proactive health—staying healthy through transformational hygiene. Xlear xylitol-based products support that goal.
From the time that Ignaz Semmelweiss first wrote about the need for physicians to wash their hands between patients and the time that it became the standard of care (or mandated because it wasn’t being done) was 150 years. Semmelweiss was ridiculed, laughed at, and discredited, but history proved him correct. Washing our hands and our nose are simple hygienic ways that we can stop the spread of bacteria and viruses.
Nasal hygiene is more important to our health than washing our hands. Washing our hands helps stop the spread of infections, but how often do you really get sick through your hands? Practically zero. You get sick when you touch your hands to your face, your nose, your eyes where bacteria and viruses can easily enter the body.
Wouldn’t it make more sense to wash our nose with something that blocks viral and bacterial adhesion?
The nose is where bacteria and viruses enter the body. Nearly 75% of the visits to primary care physicians in the U.S. are related to upper respiratory issues. We can bring that number down significantly if we start washing our nose.
Xlear Nasal Spray was developed by Dr. Lon Jones who wanted to better serve his patients with upper respiratory illnesses and conditions. After reading the extensive research done in Finland on the benefits of xylitol, Dr. Jones developed a xylitol nasal spray to treat his patients with persistent upper-respiratory infections. He successfully treated his granddaughter’s ear infections and soon began dispensing the solution to other patients with ear, nose, and throat issues.
Let’s transform our hygiene and make it more effective. Wash your nose with Xlear.
Need more convincing? Read the studies below that support cleaning your nose with Xlear.
Anti-Adherence of Bacteria – 1998
This study found that xylitol blocked adhesion of bacteria to epithelial cells, showing that xylitol inhibits bacteria from sticking to tissue, which allows the body to wash them away.
Kontiokari, T., Uhari, M., & Koskela, M. (1998). Antiadhesive effects of xylitol on otopathogenic bacteria. The Journal of Antimicrobial Chemotherapy, 41(5), 563–565.
Xylitol Nasal Irrigation in the Management of Chronic Rhinosinusitis – 2011
Airway Study – 2015
In a 2015 presentation, Dr. Nsouli shared his findings of a study which showed that a nasal spray with xylitol increased peak airflow 35% more than saline alone and measurably increased participants’ quality of life.
Nsouli, T. M.; et al., (2015) ORAL ABSTRACT #46.
Improved Nasal Volume Utilizing Hyperosmotic Saline Xylitol Mixture (Effective Alternative or Adjunct to Decongestants and Antihistamines) – 2019
High Viral Load in the Nose – Mar. 2020
In this correspondence, researchers shared their research which showed that the nose has the highest viral load of SARS-CoV-2 than elsewhere in the body when infected with the virus.
Mapping How SARS-CoV-2 Infects the Body – May 2020
In this study done at UNC Chapel Hill, researchers found that the SARS-CoV-2 virus first infects the body through the nose, establishes itself there, and then progresses into the airway and lungs.
The Three Stages of SARS-CoV-2 Infection – Jul. 2020
Benefits and Safety of Nasal Saline Irrigations in a Pandemic—Washing SARS-CoV-2 Away – Jul. 2020
Anti-Adherence of SARS-CoV-2 Virus – Aug. 2020
Using Nasal Sprays to Combat SARS-CoV-2 – Sept. 2020
Nasal Irrigation Reduces Symptoms Related to SARS-CoV-2 – Sept. 2020
Kimura, K. S., et al., (2020). Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019. International Forum of Allergy & Rhinology, 10(12), 1325–1328.
Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution with SARS-CoV-2: Case Series – Nov. 2020
Xylitol’s Method of Action against SARS-CoV-2 – Nov. 2020
Deactivation of SARS-CoV-2 with Xlear Nasal Spray – Nov. 2020
Further Evidence of Xylitol’s Effectiveness Against SARS-CoV-2, H1N1, and Other Viruses – Jan. 2021
Comprehensive Literature Review of Intranasal Therapy Against SARS-CoV-2 – Jan. 2021
Inhibition of severe acute respiratory syndrome coronavirus 2 replication by hypertonic saline solution in lung and kidney epithelial cells – Sept. 2021
Rapid initiation of nasal saline irrigation to reduce severity in high-risk COVID+ outpatients: a randomized clinical trial compared to a national dataset observational arm – 2021
Medical Disclaimer per FTC Guidelines
While there may be information on the Xlear website relating to certain conditions, including COVID, cold, flu and similar condition, should a medical condition exist, promptly see your own physician or health provider. Xlear does not offer medical diagnosis or treatment advice. Xlear makes no claims that it can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials, including COVID, cold, flu and similar condition. The information, including any scientific or clinical research, is made available for educational purposes only. This information helps people make informed decisions about potential treatment options for the various conditions referenced in the information. Xlear therefore makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments available or that may be made available. However, research is not considered conclusive. Always consult your healthcare provider with any questions.
If you take prescription medications for any of these conditions or other conditions, including sinus and related conditions such as congestion, you should consult with your physician before discontinuing use of such medications as Xlear is not intended to replace or supplement any prescription medications.
Statements with regards to Xlear products are the opinions of the individuals making them and are not necessarily the same as those of Xlear Inc.
Xlear Inc. Statement on FTC Guidelines
Recently Xlear has removed a number of scientific studies and posted disclaimers on our website and social media. We have done this at the insistence of the Federal Trade Commission. We believe the FTC has no authority to stop us from giving you accurate scientific information. Moreover, the FTC lacks the scientific/medical expertise to evaluate such data. However, we are trying to work with the FTC to fix this.
We believe that you have a right to accurate and actionable scientific studies and data. We believe that accurate scientific data and studies are vital in helping individuals make smart and informed health decisions for themselves and their families.